The relationship between affective disorders and hormonal and metabolic parameters in women with polycystic ovary syndrome

Year 2013, , 13 - 19, 01.03.2013

Nilgün Güdücü Uzay Görmüş Başak Özge Kayan Zehra Neşe Kavak İlkkan Dünder

https://doi.org/10.5799/ahinjs.01.2013.01.0227

Cited By: 1

Abstract

Objective: To understand the relationship among affec­tive disorders and hormonal and biochemical parameters in women with polycystic ovary syndrome (PCOS). Methods: Women with PCOS (n=15) were compared to body mass index and age matched control group (n=19). Beck Depression Inventory and Stait Trait Anxiety Inven­tory were used to assess the presence of depression and anxiety symptoms. Results: Depression and anxiety scores of women with PCOS correlated with free testosterone levels. Their anxi­ety scores correlated with HDL and lipoprotein-a (Lp-a), an independent marker for increased cardiovascular dis­ease. In the control group anxiety score correlated with interleukin-1β. Conclusion: There was a relationship between increased androgens and affective disorders in women with PCOS. The correlation between Lp-a and anxiety scores may be the link between affective disorders and cardiovas­cular diseases. A different mechanism may play role in the pathophysiology of affective disorders in women with PCOS. J Clin Exp Invest 2013; 4 (1): 13-19

Keywords

Polycystic ovary syndrome, testosterone, depression, anxiety

Polikistik over sendromlu kadınlarda afektif bozukluklar ile hormonal ve metabolik parametreler arasındaki ilişki

Abstract

Amaç: Polikistik over sendromlu (PKOS) hastalarda afektif bozukluklar ile hormonal ve biyokimyasal paramet­reler arasındaki ilişkiyi anlamak. Yöntemler: PKOS tanısı almış 15 hasta, yaş ve vücut kitle endeksi benzer olan kontrol grubuyla (n=19) karşı­laştırıldı. Beck Depresyon Ölçeği ve Durumluk-Sürekli Anksiyete Ölçeği kullanılarak anksiyete ve depresyon semptomları sorgulandı. Bulgular: Polikistik over sendromlu hastaların depres­yon ve anksiyete skorları serbest testosterone seviyeleri ile korele idi. Anksiyete skorları HDL ve kardiyovasküler hastalıklar için bağımsız bir risk faktörü olarak kabul edi­len lipoprotein-a ile koreleydi. Kontrol grubunda anksiyete skorları interlökin 1beta ile koreleydi. Sonuç: Polikistik over sendromlu hastalarda androjenler ve afektif bozukluklar arasında bağlantı vardır. Lipopro­tein-a ve anksiyete skorları arasındaki korelasyon afek­tif bozukluklar ve kardiyovasküler hastalıklar arasındaki bağ olabilir. Polikistik over sendromlu kadınlarda afektif bozuklukların patofizylojisinde farklı bir mekanizma rol oynayabilir.

Keywords

Polikistik over sendromu, testostero­ne, anksiyete, depresyon

References

• Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-861.
• Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002;252:283-294.
• Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depres- sion. Trends Immunol 2006;27:24-31.
• Raikkonen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation Definitions. Diabetes Care 2007;30:872-877.
• Skilton MR, Moulin P, Terra JL, Bonnet F. Associations between anxiety, depression, and the metabolic syn- drome. Biol Pschiatry 2007;62:1251-1257.
• Cinar N, Kizilarslanoğlu MC, Harmanci, et al. Depres- sion, anxiety and polycystic ovary syndrome. Hum Reprod 2011;26:3339-3345.
• The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consen- sus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
• Güngör O, Erden G, Bal C, et al. The comparison of free androgen index and serum free testosterone lev- els in women with hirsutism or polycystic ovary syn- drome. J Clin Exp Invest 2011;2:152-156.
• Benson S, Janssen OE, Hahn S, et al. Obesity, depres- sion, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain, Behavior, and Immunity 2008;22:177-184.
• Keegan A, Liao LM, Boyle M. ‘Hirsutism’: a psycho- logical analysis. J Health Psychol 2003;8:327-345.
• Mansson M, Holte J, Landin-Wilhemsen K, et al. Women with polycystic ovary syndrome are often de- pressed and anxious- a case control study. Psycho- neuroendocrinology 2008;33:1132-1138.
• McCook JG, Reame NE, Thatcher SS. Health-re- lated quality of life issues in women with polycystic ovary syndrome J Obstet Gynecol Neonatal Nurs 2005;34:12-20.
• Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003;74:299- 304
• Adali E, Yildizhan R, Kurdoglu M, et al. The relation- ship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res 2008;36:1188-1196.
• Hollinrake E, Abreu A, Maifeld M, et al. Increased risk of depressive symptoms in women with polycystic ovary syndrome. Fertil Steril 2007;87:1369-1372.
• Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovary syndrome to healthy controls. Psychosom Med 2004;66:356-362.
• Jedel E, Gustafson D, Waern M, et al. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with poly- cystic ovary syndrome. Psychoneuroendocrinology 2011;36:1470-1479.
• Dokras A, Clifton S, Futterweit W, et al. Increased risk for abnormal depression scores in women with poly- cystic ovary syndrome: a systematic review and meta- analysis. Obstet Gynecol 2011;117:145-152.
• Weber B, Lewicka S, Deuschle et al. Testosterone, androstenedione and dihydrotestosterone concentra- tions are elevated in female patients with major de- pression. Psychoneuroendocrinology 2000;25:765- 771.
• Morsink LFJ, Vogelzangs N, Nicklas BJ, et al. Health ABCs. Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. Psycho- neuroendocrinology 2007;32:874-883.
• Miller KK, Perlis RH, Papakostas GI, et al. Low dose transdermal testosterone augmentation therapy im- proves depression severity in women. CNS Spectr 2009;14:688-694
• Moghetti P, Castello R, Negri C, et al. Metformin ef- fects on clinical features, and endocrine and meta- bolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo con- trolled 6 month trial, followed by open, long-term clini- cal evaluation. J Clin Endocrinol Metab 2000;85:139- 146.
• Sverissidottir YB, Mogren T, Kataoka J, et al. Is poly- cystic ovary syndrome associated with high sympa- thetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 2008;294:576-581.
• Feng Y, Shao R, Weijdegard B, et al. Effects of andro- gen and leptin on behavioral and cellular responses in female rats. Hormones and Behavior 2011;60:427- 438.
• Benson S, Arck PC, Tan S, et al. Disturbed stress re- sponses in women with polycystic ovary syndrome. Psychoneuroendocrinology 2009;34:727-735.
• Maes M, Scharpe S, Meltzer HY, et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 1993;49:11-27.
• Piletz JE, Halaris A, Igbal O, et al. Pro-inflammatory markers in depression: Treatment with venlafaxine. World J Biol Psychiatry 2009;10:313-323.
• Livadas S, Chaskou S, Kandaraki AA, et al. Anxiety is associated with hormonal and metabolic profile in women with polycystic ovarian syndrome. Clin Endo- crinol 2011;75:698-703.
• Hahn S, Benson S, Elsenbruch S, et al. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress, and sexuality. Hum Reprod 2006;2:1925-1934.
• Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod 2010;16:347-363 .
• Berneis K, Rizzo M, Hersberger M, et al. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract. 2009;63:56-62.